ANTIMIKOTIKI DLYa SISTEMNOGO PRIMENENIYa: KLYuChEVYE ASPEKTY DLYa KLINITsISTA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Antifungal agents (AA) for systemic use can be categorized as life-saving drugs. The increase in the number of IFI requires not only competent diagnostic actions, but also the timely appointment of adequate clinical and pharmacological characteristics of antifungal therapy. Despite the small number of available AA for systemic use, they have a number of fundamental differences that should be considered when choosing a drug. Now five main groups of AA are available: the polyenes, azoles, echinocandins, allylamines and fluoropyrimidines. Each group has its own characteristics in the spectrum of activity, pharmacokinetics, safety, and indications for use, including differences within the one class that is most characteristic of azoles. Knowledge of the epidemiology of the sensitivity of fungal pathogens is another important component of an adequate choice of therapy.

Full Text

Restricted Access

About the authors

A. V Veselov

Email: alex.veselov@antibiotic.ru

References

  1. Brown G., Denning D., Gow N., Levitz S., Netea M., White T. Hidden killers: human fungal infections. Sci. Transi. Med. 2012;4(165):165rv13.
  2. Odds F., Brown A., Gow N. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272-79.
  3. Cleveland A., Farley M., Harrison L., Stein B., Hollick R., Lockhart S. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 2012;55(10):1352-61.
  4. Groll A., Gea-Banacloche J., Glasmacher A., Just-Nuebling G., Maschmeyer G., Walsh T. Clinical pharmacology of antifungal compounds. Infect. Dis. Clin. North. Am. 2003; 17(1):159-91.
  5. Lepak A, Andes D. Antifungal Pharmacokinetics and Pharmacodynamics. Cold Spring Harb. Perspect Medю 2014;10(5):5.
  6. Hamill R. Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs. 2013;73:919-34.
  7. Cornely O., Maertens J., Bresnik M., AmBiLoad Trial Study Group. Liposomal amphotericine B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 2007;44:1289-97.
  8. Sheehan D., Hitchcock C., Sibley C. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 1999;12(1):40-79.
  9. Веселов А.В., Климко Н.Н., Кречикова О.И., Клясова Г.А., Агапова Е.Д., Мултых И.Г., Розанова С.М., Крайнова Л.Е., Дмитриева Н.В., Козлов Р.С. In vitro активность флуконазола и вориконазола в отношении более 10000 штаммов дрожжей: результаты 5-летнего проспективного исследования ARTEMIS Disk в России. Клин. микробиол. антимикроб. химиотер. 2008;10(4):345-54.
  10. Klimko N., Vasilyeva N., Chernenkaya T., Kutsevalova O., Vetokhina A., Mukhacheva S., Basin E., Saturnov A., Bogomolova T., Shagdileeva E., Raush E. Invasive candidiasis in intensive care units: results of prospective multicentre study in Russia. Proceedings of 25th ECCMID, Copenhagen, Denmark, April 25-28, 2015. Poster #EV0945.
  11. Pfaller M., Castanheira M., Messer S., Moet G., Jones R. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn. Microbiol. Infect. Dis. 2010;68:278-83.
  12. Maertens J. History of the development of azole derivatives. Clin. Microbiol. Infect. 2004;10(Suppl 1):1-10.
  13. Государственный реестр лекарственных средств. Доступно по адресу http://grls.ros-minzdrav.ru.
  14. Pappas P., Kauffman C., Andes D., Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009; 48(5):503-35.
  15. Cornely O., Bassetti M., Calandra T., for the ESCMID Fungal Infection Study Group (EFISG). ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 2012;18(Suppl 7):19-37.
  16. Dolton M., McLachlan A. Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Curr. Opin. Infect. Dis. 2014;27(6):493-500.
  17. De Beule K., Van Gestel J. Pharmacology of Itraconazole. Drugs. 2001;61(Suppl 1):27-37.
  18. Ashbee R., Barnes R., Johnson E., Richardson M., Gorton R., Hope W. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J. Antimicrob. Chemother. 2014;69:1162-76.
  19. Kofla G., Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin. Pharmacother. 2005;6(7):1215-19.
  20. Bartelink I., Wolfs T., Jonker M., de Waal M., Egberts T., Ververs T. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob. Agents Chemother. 2013;57(1):235-40.
  21. Bayhan G., Garipardic M., Karaman K., Akbayram S. Voriconazole-associated visual disturbances and hallucinations. Cutan. Ocul. Toxicol. 2015;Mar 23:1-3. [Epub ahead of print].
  22. Perfect J., Hachem R., Wingard J. Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. Clin. Infect. Dis. 2014;59(Suppl 5):S352-55.
  23. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 2004;58:612-14.
  24. Allen D., Wilson D., Drew R., Perfect J. Azole antifungals: 35 years of invasive fungal infection management. Expert Rev. Anti. Infect. Ther. 2015;13(6):787-98.
  25. Ullmann A., Akova M., Herbrecht R., for the ESCMID Fungal Infection StudyGroup (EFISG). ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin. Microbiol. Infect. 2012; 18(Suppl 7):53-67.
  26. Onishi J., Meinz M., Thompson J., Curotto J., Dreikorn S., Rosenbach M. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 2000;44(2):368-77.
  27. Pfaller M., Messer S., Boyken L., Rice C., Tendolkar S., Hollis R., Diekema D. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J. Clin. Microbiol. 2003;41(12):5729-31.
  28. Bowman J., Abruzzo G., Flattery A., Gill C., Hickey E., Hsu M. Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob. Agents Chemother. 2006;50(12):4202-205.
  29. Kofla G, Ruhnke M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur. J. Med. Res. 2011;16(4):159-66.
  30. Lewis J., Wiederhold N., Wickes B., Patterson T., Jorgensen J. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob. Agents Chemother. 2013;57(9):4559-61.
  31. Alexander B, Johnson M., Pfeiffer C., Jimenez-Ortigosa C, Catania J., Booker R. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibi tory concentrations. Clin. Infect. Dis. 2013; 56(12):1724-32.
  32. Spreghini E., Orlando F., Tavanti A., Senesi S., Giannini D., Manso E., Barchiesi F. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J. Antimicrob. Chemother. 2012;67(9):2195-202.
  33. Arendrup M.C., Cuenca-Estrella M., Lass-Florl C., Hope W. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist. Updat. 2013;16(6):81-95.
  34. Dowell J., Stogniew M., Krause D., Henkel T., Weston I. Assessment of the safety and pharmacokinetics of anidulafungin when admin istered with cyclosporine. J. Clin. Pharmacol. 2005;45:227-33.
  35. EMEA. Mycamine. Summary of product characteristics. Available from: http://www.ema.euro-pa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/000734/ WC500031075.pdf.
  36. Vermes A., Guchelaar H.-J., Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity, and drug interactions. J. Antimicrob. Chemother. 2000;46:171-79.
  37. Inano S., Kimura M., Iida J., Arima N. Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review. J. Infect. Chemother. 2013;19(6):1173-80.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media